Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
This comparison highlights essential contrasts between Zero Based and Incremental budgeting, focusing on allocation, rigor, and outcomes.
17,319 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Target’s new chief executive Michael Fiddelke unveils a candor-driven plan to revive growth after a sales slump. The ...
One year after the pledge, the Strategic Petroleum Reserve remains short of full capacity while crude prices push pas...
A rumored alliance between AMD and Meta Platforms could reshape AI hardware and software ecosystems. This article exa...
Investors are weighing XRP's chances as regulatory risk and crypto sentiment shift. This guide breaks down why here's...
Rising energy costs are pushing fertilizer prices higher, with the potential to lift grocery bills in the coming mont...
Tech stocks lead early gains as oil eases and AI developments grab attention. The live Nasdaq Composite shows tech st...
In a volatile economy, boards are adjusting performance targets to preserve executive compensation. This piece explai...
Meta Platforms paused the public rollout of its Avocado AI model to focus on quality, while expanding its Hyperion da...
A seasoned CEO message can move markets, especially in AI era. This deep dive explains what broadcom hock just delive...
Lenders posted healthier profits per loan in Q3 2025, but declined loans still drain resources. A new declined loan a...
Braze beat Q4 expectations with $205.17 million in revenue and 27.9% annual growth, as analysts weigh the AI-driven g...